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Abstract
Background: Recent studies have revealed that cyclooxygenase-2 (COX-2) expression is down-regulated in aspirin-induced
asthma (AIA). Various signal pathways (MAPKs, NF-kB and C/EBP) are involved in COX-2 regulation.
Objective: To investigate the regulation of COX-2 expression through MAP-kinase pathway activation and nuclear factor
translocation in aspirin-induced asthma (AIA).
Methods: Fibroblasts were isolated from specimens of nasal mucosa (NM, N = 5) and nasal polyps (NP, N = 5). After IL-1b
(1 ng/ml) incubation, COX-2 and phosphorylated forms of ERK, JNK and p38 MAPK were measured by Western blot. MAPK’s
role in IL-1b-induced COX-2 expression was assessed by treating cells with ERK (PD98059), JNK (SP600125) and p38 MAPK
(SB203580) inhibitors (0.1–10 mM) prior to IL-1b exposure. NF-kB and C/EBP nuclear translocation was measured by Western
blot and TransAMH after IL-1b (10 ng/ml) exposure.
Results: No differences were observed in the MAPK phosphorylation time-course between NM and NP-AIA fibroblasts. The
p38 MAPK inhibitor at 10 mM significantly reduced IL-1b-induced COX-2 expression in NM fibroblasts (85%). In NP-AIA
fibroblasts the COX-2 inhibition (65%) at 1 and 10 mM was not statistically significant compared to non-treated cells. ERK
and JNK inhibitors had no significant effect in either the NM or NP-AIA cultures. The effect of IL-1b on NF-kB and C/EBP
subunits’ nuclear translocation was similar between NM and NP-AIA fibroblasts.
Conclusions: These results suggest that p38 MAPK is the only MAPK involved in IL-1b-induced COX-2 expression. NM and
NP-AIA fibroblasts have similar MAPK phosphorylation dynamics and nuclear factor translocation (NF-kB and C/EBP). COX-2
downregulation observed in AIA patients appears not to be caused by differences in MAPK dynamics or transcription factor
translocation.
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Fundación Respira (Spanish Respiratory Society). The funders had no role in the study design, data collection or analysis, or the decision to publish, or the
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: idib402@clinic.ub.es
. These authors contributed equally to this work.
Introduction
Aspirin-induced asthma (AIA) is a syndrome clinically charac-
terized by chronic rhinosinusitis with nasal polyposis (CRSwNP),
asthma and bronchoconstriction episodes triggered by the intake
of non-steroidal-anti-inflammatory drugs (NSAIDs) [1]. A close
relationship has been demonstrated between CRSwNP and AIA,
since the prevalence of CRSwNP in AIA may be as high as 60–
70%, while in the population of aspirin-tolerant asthmatics it is less
than 10% [2].
The pathogenesis of AIA remains poorly understood but
accumulated evidence suggests that abnormalities in arachidonic
acid metabolism may play a role [2,3]. Both an overactive 5-
lipoxygenase pathway (5-LO) and reduced COX expression have
been demonstrated, resulting in increased cysteinyl leukotriene
production and reduced PGE2 release in AIA [1,4–7]. There are
two well-characterized COX enzymes: COX-1, considered a
constitutive form involved in cell homeostasis [8], and COX-2, an
inducible form activated by pro-inflammatory mediators, growth
factors and cytokines. These alterations in AIA patients seem to be
present in both the lower [6] and upper airways [4]. In fact,
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previous studies have reported COX-2 down-regulation in airway
fibroblasts obtained from AIA patients [7]. In contrast with
asthma, increased COX-2 expression has been reported in other
airway inflammatory diseases such as cystic fibrosis [9] and
chronic obstructive pulmonary disease [10].
The mechanisms responsible for the reported alterations in the
regulation of COX-2 in inflamed NP tissue remain to be clarified.
It is well known that inflammatory stimuli elicit cellular responses
through the activation of mitogen-activated protein kinases
(MAPKs) by phosphorylation. MAPKs regulate various cellular
activities, including gene expression, mitosis and programmed
death. MAPK-catalyzed phosphorylation functions as a switch for
turning the activity of their target proteins on/off [11,12].
In pluricellular organisms, there are three well-characterized
subfamilies of MAPKs: extracellular-signal-regulated kinases, p42/
44 (ERK1/2), c-jun amino terminal kinases (JNKs) and p38
MAPKs [11,12]. So far, it has been demonstrated that MAPK
family members play a role in COX-2 gene expression in various
cell types, such as HUVECs [13], airway smooth muscle cells [14]
and chondrocytes [15]. However, the role of the various MAPKs
regulating COX-2 in AIA has never been studied.
COX-2 gene expression is also regulated by the action of several
transcription factors, such as NF-kB [16–18] and C/EBP [19]. It
has been widely demonstrated that NF-kB regulates cell survival
and inflammatory responses by acting, at least in part, on the two
active kB binding sites described in the COX-2 promoter gene
[16,20–22]. Active NF-kB complexes are dimers of combinations
of Rel family polypeptides (p50, p52 and p65) that respond to a
wide variety of stimuli. The composition of NF-kB dimmers
partially determines their biological effects by conditioning nuclear
translocation and binding to the kB-regulatory elements [16,20].
There is also a C/EBP binding site on the human COX-2
promoter, which is involved in COX-2 induction. The three main
members of the C/EBP family are C/EBPa, C/EBPb and C/
EBPc. Their nuclear translocation is induced by pro-inflammatory
stimuli, but although all C/EBPs subunits recognize the same
DNA sequence, the balance between them and the cell type will
determine the activation or repression of the gene expression [23–
25]. However, the regulation of NF-kB and C/EBP transcription
factors in fibroblasts from AIA patients has not been studied.
We hypothesized that the COX-2 down-regulation observed in
AIA patients is caused by alterations in the mechanisms regulating
the activation of MAPKs and nuclear factor translocation (NF-kB,
and C/EBPs). As we have demonstrated in previous studies that
the anomalies in the regulation of COX-2 are present in cultured
fibroblasts obtained from the NP of AIA patients, the objective of
our study was to examine the activation of MAPKs and nuclear
factor translocation (NF-kB, and C/EBPs) in fibroblasts derived
from nasal mucosa, and from the NP of AIA patients.
Materials and Methods
Study Population
NM specimens were obtained from the lower turbinate of 5
non-asthmatic subjects with either septal deviation, turbinate
hypertrophy or both who were undergoing nasal corrective
surgery. All control subjects had taken aspirin or NSAIDs at
clinical dosage without any untoward reactions (asthma and/or
rhinitis, urticaria, angioedema or anaphylaxis). NP specimens were
collected from patients with aspirin intolerance (NP-AIA) who had
undergone endoscopic sinus surgery. The clinical and demo-
graphic characteristics of the subjects are shown in Table 1. The
diagnosis of aspirin intolerance was confirmed by lysine-aspirin
nasal challenge, as previously described [26]. None of the control
subjects had received oral or intranasal corticosteroid treatment
for at least one month before surgery. None of the control subjects
or patients had any upper airway infection in the 2 weeks before
surgery.
Ethical Declaration
All patients gave their written informed consent to participate in
the study, which was approved by the Scientific and Ethics
Committee (Comité Étic d’Investigació Clı́nica) of our Institution
(Hospital Clı́nic de Barcelona).
Tissue Handling and Cell Culture
NM and NP tissues were cut into 363 mm fragments and
placed in six-well plates (NUNC, Wiesbaden, Germany) contain-
ing Dulbecco’s modified Eagle’s media (DMEM) supplemented by
10% fetal bovine serum (FBS), 100 IU/ml penicillin, 100 mg/ml
streptomycin (Invitrogen, Carlsbad, California, USA) and 2 mg/ml
amphotericin B (Sigma, St Louis, MO, USA). Cultures were
placed in a 5% CO2 humidified incubator at 37uC and the culture
media were changed every 2 days. Once the fibroblasts had
grown, tissue fragments were removed and the first passage was
performed by adding 0.05% trypsin/0.02% ethylenediaminetet-
raacetic acid (Invitrogen, Carlsbad, California, USA) for 5 min.
The reaction was stopped with 10% FBS-supplemented DMEM.
Cells were then centrifuged (400 g, 5 min) and seeded in 150 cm2
flasks (NUNC). At passages 5 to 6, fibroblasts were cultured in
CultureSlidesH and flasks to perform culture characterization and
experimental protocols. The same batch of FBS was used for the
whole experimental period. Mycoplasma contamination was tested
by PCR in the cultures and all of them were negative.
Cell Characterization
Characterization of cultured cells was performed by immuno-
fluorescence for fibroblasts (vimentin) and epithelial cells (cytoker-
atins) on CultureSlidesH incubated with serum-free media (SFM)
for 24 h. Immunofluorescence assessment was performed as
previously reported [11]. The primary antibodies were against
vimentin at dilution 1:100 (V5255, Sigma, Saint Louis, Missouri,
USA) and pan-cytokeratin at 1:200 (C2562, recognizing cytoker-
atins 1, 4, 5, 6, 8, 10, 13, 18 and 19, Sigma). The percentage of
positive cells was quantified using fluorescence microscopy.
Study Design
When cultures placed in 150 cm2 flasks reached 80% conflu-
ence, FBS-supplemented media were switched to serum-free
Table 1. Epidemiological characteristics of control subjects
and patients with NP and AIA.
Characteristics NM fibroblasts NP-AIA fibroblasts
Fibroblast cultures, N 5 5
Age, years (mean ± SD) 55.6614.5 59.6611.9
Females, N (%) 3 (60) 4 (80)
Asthma, N (%) 0 (0) 5 (100)
Aspirin intolerance, N (%) 0 (0) 5 (100)
Atopy, N (%) 0 (0) 2 (40)
Intranasal corticosteroid, N
(%)
0 (0) 3 (60)
SD, standard deviation.
doi:10.1371/journal.pone.0051281.t001
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media (SFM) for 24 h. To analyze COX expression, the dynamics
of MAPK phosphorylated forms and transcription factor nuclear
translocation, cells were incubated with SFM in the presence or
absence of IL-1b (R&D Systems Minneapolis, MN, USA) at
different concentrations and for different times, depending on the
protein analyzed. Meanwhile, in experiments on MAPK inhibition
fibroblasts were pre-treated with ERK (PD98059), JNK
(SP600125) and p38 MAPK (SB203580) inhibitors from Calbio-
chem (La Jolla, CL, USA) at different concentrations (0.1–10 mM)
for 1 h, prior to the addition of 1 ng/ml IL-1b for 24 h. Total
proteins were obtained by scraping the flasks after two washes with
cold PBS. The cells were centrifuged (400 g, 5 min at 4uC) and
then resuspended in different buffers, depending on the protein
quantified and the analytical method.
Analysis of COX Expression by Western Blot
Fibroblast cultures were incubated with IL-1b (1 ng/ml) from 0
to 24 h in time-course experiments, and for 24 h with IL-1b (0–
10 ng/ml) in dose-response experiments. Cell pellet was resus-
pended in 0.4 ml ice-cold lysis buffer (CompleteTM protease
inhibitor cocktail tablet in 50 ml of 0.05 M Hepes buffer solution,
0.05% v/v Triton X-100, and 625 mM PMSF). Cells were
sonicated twice for 15 sec in a sonifier (Branson, Danbury, CT,
USA) and centrifuged (12,000 g, 10 min at 4uC). Supernatant
containing total proteins was quantified by Lowry’s method and
used to analyze COX-1 and COX-2 protein expression by
Western blot, as described previously (11). The primary antibodies
used were against COX-1 (SC-1752, Santa Cruz) or COX-2 (SC-
1745, Santa Cruz) at dilution 1:1000. Immunoreactive bands were
visualized using a chemoluminiscent method (Supersignal West
Pico Chemiluminescent Substrate, Rockford, IL, USA). Light
emissions were detected by the CCD Camera System LAS 3000
(Fujifilm, Tokyo, Japan). Band intensities were quantified with
Fujifilm Image Gauge 4.0 Software, and normalized by b-actin
band intensities assessed in the same samples.
Analysis of the Dynamics of MAPK Phosphorylated Forms
by Western Blot
Fibroblast cultures were incubated with 1 ng/ml IL-1b from 0
to 60 min. Cell pellet was resuspended with an insulin syringe in
ice-cold Rippa buffer (TrisHcl 50 mM+Nacl 150 mM, ph 7.4,
apropine 1:1000, leupeptine 1:1000, ortovanadate 1:1000, NaF
1 mM, DTT 1 mM, pefabloc 100 mg/ml, igepal 1%, SDS 0.1%
and Na deoxicolat 0.5%). The samples were in ice for 1 h and
then centrifuged (12,000 g, 10 min at 4uC). Supernatant contain-
ing total proteins was quantified by Lowry’s method and used to
analyze phosphorylated and non-phosphorylated forms of MAPKs
by Western blot. Briefly, 20 mg of proteins in loading buffer were
denaturalized in a thermocycler (70uC, 10 min), loaded in 12%
TRIS-glycine gels and ran (125 V, 90 min) in a Novex XCell II
Mini-Cell. Proteins were transferred (20 V, 2 h) to a 0.45 mm pore
size nitrocellulose membrane and non-specific binding sites were
blocked using blocking buffer (5% BSA, 0.1% Tween 20, in
10 nM TBS) for 1 h at room temperature in an orbital shaker.
The membranes were then washed three times in 0.1% Tween 20,
in 10 nM TBS and incubated overnight with the primary antibody
buffer (5% BSA and 0.1% Tween 20 in 10 nM TBS). The primary
antibodies used were p-p38 MAPK at 1:1000 (9215, Cell
Signalling Technology, Inc, Beberly, Mass, USA), p38 MAPK at
1:1000 (9212, Cell Signalling), p-JNK at 1:1000 (4668, Cell
Signalling), JNK at 1:1000 (9258, Cell Signalling), p-ERK at
1:2000 (4370, Cell Signalling) and ERK at 1:2000 (4695, Cell
Signalling). The membranes were then washed four times in
washing buffer (0.1% Tween 20 in 10 nM TBS) and incubated
with peroxidase-conjugated secondary antibody (1:3000) diluted in
blocking buffer. After four washes, immunoreactive bands were
visualized using a chemoluminiscent method (Supersignal West
Dura Chemiluminescent Substrate, Rockford, IL, USA). Light
emissions were detected by the CCD Camera System LAS 3000
(Fujifilm, Tokyo, Japan). Band intensities were quantified with
Fujifilm Image Gauge 4.0 Software and normalized by the non-
phosphorylated form of the respective MAPKs studied. The b-
actin protein was assessed as a loading control.
MAPK Inhibition Analysis by Western Blot
Cell pellet was resuspended in 0.4 ml ice-cold lysis buffer,
sonicated twice for 15 sec and centrifuged (12,000 g, 10 min at
4uC). Supernatant containing total proteins was quantified by
Lowry’s method and used to analyze COX-2 protein expression
by Western blot, as described above.
Isolation of Nuclear Proteins
Fibroblasts cultures were incubated with 10 ng/ml IL-1b from 0
to 60 min. Since activated transcription factors translocate to the
nucleus, the Active Motif Nuclear Extract Protocol (Active Motif,
Carlsbad, CA, USA) was used to isolate nuclear proteins. The
purity of the nuclear fractions was assayed using LDH (AB 1222,
Millipore, Chemicon International, Temecula, CA, USA) as a
cytosolic marker.
Analysis of Transcription Factors Translocation by ELISA-
based Kits
The presence in nuclear extracts of p50, p52, p65, c/EBPa and
C/EBPb was measured with the ELISA-based kit TransAMH
(Active Motif, Carlsbad, CA, USA), according to the manufacturer
instructions. The colorimetric reading at 450 nm was determined
in a microplate reader MultiScan Ascent (Thermo, Rockford, IL,
USA). The positive-control Jurkat nuclear extract provided with
the kit was used to quantify the samples and assess assay specificity.
Analysis of Transcription Factor Translocation by Western
Blot
Since Western blot was performed to confirm the TransAMH
findings, only the transcription factors that showed an increase in
translocation with this ELISA-based method were analyzed.
Nuclear extracts (30 mg) quantified by the Lowry method were
denaturalized in thermocycler, loaded in 7% TRIS-acetate gel and
run (125 V for 90 min) in a Novex XCell II Mini-Cell. The
protein was then transferred (20 V 2 h) to an 0.45 mm pore-size
nitrocellulose membrane and non-specific sites were blocked with
blocking buffer for 1 h at RT in an orbital shaker. The membranes
were incubated with the primary antibody against p65 (SC-372-G,
Santa Cruz), p50 (SC-1190, Santa Cruz) in blocking buffer
(1:1,000). The membranes were then washed 4 times in 0.5 Tween
20 in 10 nmol/L PBS and incubated with the peroxidase-
conjugated secondary antibody (1:1000) diluted in blocking buffer.
The bands were visualized as described in the COX Western blot
section.
Statistic Analysis
The data obtained from MAPK phosphorylation are expressed
as median of the ratio phosphorylated:non-phosphorylated form.
Results obtained from MPAK inhibition are expressed as medians
and 25th–75th interquartiles of the COX-2 expression, compared
to IL-1b treated cells. Data obtained from ELISA-based kits are
expressed as fold change increase median of the ratio transcription
factor versus positive control. The non-parametric statistical
COX-2 Signalling in Aspirin Intolerance
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Mann-Whitney U-test was used for between-group comparisons
and the Wilcoxon test was used for paired comparisons. Statistical
significance was set at p,0.05.
Results
COX Expression
Basal COX-1 expression was not different between NM and
NP-AIA fibroblasts. After IL-1b incubation in time-course and
dose-response experiments, COX-1 expression was not modified
in NM (N = 3) and NP-AIA (N = 3) cultured fibroblasts (Figure 1).
COX-2, basal protein expression was not detected in either the
NM or NP-AIA fibroblasts. However, fibroblasts from NM
showed an increase in COX-2 expression, in a time-course and
dose-response manner, after IL-1b incubation, with the highest
COX-2 expression coming after 24 h of treatment with IL-1b at 1
and 10 ng/ml. In contrast, incubation with IL-1b at 24 h did not
change COX-2 protein expression in cultured fibroblasts from the
NP of AIA, compared to the baseline (Figure 1).
MAPK Activation
A trend towards increased ratios of phosphorylated versus non-
phosphorylated forms of the studied MAPKs (p38 MAPK, JNK
and ERK) were observed after 5 min of IL-1b incubation in both
NM and NP-AIA fibroblast cultures. In NM, the phosphorylation
kinetics of p38 MAPK, JNK and ERK reached their maximum at
15 min. However, in NP-AIA the maximum phosphorylation level
was observed at 5 min for both p38 MAPK and ERK, and at
15 min for JNK. The phosphorylation level of p38 MAPK, JNK
and ERK reverted to close to the basal level at 60 min in both the
NM and NP-AIA fibroblast cultures. Nevertheless the observed
trends did not achieve statistical significance compared to baseline
(Figure 2). A comparison of the ratios of phosphorylated versus
non-phosphorylated MAPK forms showed no significant differ-
ences between NM and NP-AIA fibroblasts.
MAPK Inhibition
In NM, incubation with p38 MAPK inhibitor SB203580 at
10 mM significantly decreased IL-1b-induced COX-2 protein
expression (85%). In NP-AIA, p38 MAPK specific inhibitor
decreased IL-1b-induced COX-2 protein expression at 1 mM
(65%) and 10 mM (65%), although statistical significance was not
achieved (p = 0.06), probably due to the low COX-2 induction
levels in these cells. As regards JNK and ERK inhibition, both
failed to modify COX-2 protein expression in NM and NP-AIA
fibroblasts (Figure 3). Finally, when comparing the effects of the
different specific inhibitors on COX-2 expression, no significant
differences were found between NM and NP-AIA fibroblasts.
Transcription Factor Nuclear Translocation
The analysis by TransAMH of p50 and p65 subunits showed the
presence of these subunits at basal level in both NM and NP-AIA
fibroblasts. Treatment with IL-1b induced the nuclear transloca-
tion of subunits p50 and p65, with a trend towards maximum
translocation at 30 min and a decrease at 60 min in NM
fibroblasts. In NP-AIA the trend towards maximum translocation
was reached at 15 min and a plateau effect was maintained until
60 min. However, the observed trends did not achieve statistical
significance compared to baseline. Western blot was performed
with the same samples and the obtained images suggested similar
kinetics (Figure 4). TransAMH measures revealed that the
nuclear presence of C/EBPa, C/EBPb (Figure S1) and p52
was not modified after IL-1b incubation of NM and NP-AIA
fibroblasts. No statistically significant differences were found
compared at any time in p50, p65, p52, C/EBPa and C/EBPb
protein expression between NM and NP-AIA fibroblasts.
Figure 1. Time-course and dose-response of IL-1b in COX-1 and COX-2 protein expression. Fibroblasts from nasal mucosa (NM) and nasal
polyps from AIA patients (NP-AIA) were incubated at different times and concentrations with IL-1b. COX-1 expression was not altered by IL-1b
treatment in either NM or NP-AIA fibroblasts. In NM fibroblasts, COX-2 expression was induced in a time-dependent and dose-response manner. In
NP-AIA, COX-2 protein expression was not significantly increased, compared to baseline level. The image that is shown is representative of NM and
NP-AIA Western blot.
doi:10.1371/journal.pone.0051281.g001
COX-2 Signalling in Aspirin Intolerance
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e51281
Discussion
Reduced COX-2 expression, and consequently decreased PGE2
concentration, has previously been reported in peripheral blood
leukocytes (PBLs) [27], urine [28], nasal polyps [29] and nasal
polyp fibroblasts [7] in a variety of cells and samples from AIA
patients, although the mechanism involved in this alteration
remain unclear. To investigate the potential mechanisms under-
lying differences in the COX pathway of arachidonic acid in AIA,
we used a previously published in vitro model [7] in which IL-1b
induced lower COX-2 expression in NP-AIA fibroblasts compared
with NM fibroblasts.
We hypothesized that the observed anomalies of COX-2
expression under inflammatory conditions were caused by
differences in the signalling pathways, MAPK activation or
nuclear transcription factor translocation between fibroblasts
derived from NM and those obtained from NP of AIA patients.
The transient increase in phosphorylated levels in NP-AIA,
peaking at 5 min (p38 MAPK and ERK) and 15 min (JNK) post-
stimulation, were similar to those previously reported in stromal
cells [30] and keratocyst fibroblasts [31], demonstrating the ability
of IL-1b to activate MAPK signalling. To examine the involve-
ment of the three main MAPK pathways in COX-2 gene
expression regulation, NM and NP-AIA fibroblasts were incubated
with selective MAPK inhibitors. ERK and JNK specific inhibitors
had no significant effect on COX-2 induced expression. In
contrast, a selective p38 MAPK inhibitor significantly reduced the
IL-1b-induced COX-2 expression in NM fibroblasts, while only a
tendency towards the inhibition of COX-2 expression was
observed in NP. The latter finding can be explained by the
difficulties in demonstrating differences in the inhibition of the
expression of a gene (COX-2 gene) that changes very little after
stimulation. All in all, these findings suggest that the p38 MAPK
pathway is the transcription factor most involved in the regulation
of COX-2 expression in nasal fibroblasts.
Our finding concurs with Chen et al. [32], who demonstrated
the importance of p38 MAPK in COX-2 regulation in human
pulmonary epithelial cells and the lack of involvement of ERK.
Figure 2. Time-course of MAPK activation by IL-1b in nasal fibroblasts cultures. Fibroblasts from nasal mucosa (NM, N = 4, black spots) and
nasal polyps from AIA patients (NP-AIA, N = 4, white spots) were incubated with IL-1b (1 ng/ml) for 5 to 60 min. Phosphorylated and non-
phosphorylated forms of p38 MAPK (A), JNK (B), and ERK (C) were measured by Western blot. Results are expressed as the ratio of phosphorylated
versus non-phosphorylated MAPK forms. Graph shows individual experimental results and lines indicate the medians values. MAPK dynamic
activation was not different (NS, Mann-Whitney U-test) between NM and NP-AIA fibroblasts. Insets show representative Western blot images of p38
MAPK, JNK, and ERK phosphorylation dynamics and b-actin as loading control.
doi:10.1371/journal.pone.0051281.g002
COX-2 Signalling in Aspirin Intolerance
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e51281
Figure 3. Effect of MAPK specific inhibitors on COX-2 protein expression. Fibroblasts from nasal mucosa (NM, N = 5, black spots) and nasal
polyps from AIA patients (NP-AIA, N = 5, white spots) were pre-treated with p38 (A) MAPK (SB203580), (B) JNK (SP600125), and (C) ERK (PD98059)
specific inhibitors at different concentrations (0.1–10 mM) for 1 h before addition of IL-1b (1 ng/ml) for 24 h. COX-2 and b-actin protein expression
was analyzed by Western blot. Only the p38 MAPK inhibitor significantly blocked IL-1b-induced COX-2 expression in NM fibroblasts. Results are
presented as COX-2/b-actin ratio. Graph shows individual experimental results and lines indicate the medians values. * p,0.05, { p = 0.06 compared
to IL-1b treatment by Wilcoxon test.
doi:10.1371/journal.pone.0051281.g003
COX-2 Signalling in Aspirin Intolerance
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Similarly, Ulivi et al. [21] also showed that p38 MAPK plays a
critical role in COX-2 regulation in chondrocytes under inflam-
matory conditions.
IL-1b treatment induced rapid nuclear translocation of p50 and
p65 NF-kB subunits in both NM and NP-AIA fibroblasts. In
keeping with this result, previous reports have shown similar
findings in several cell types, such as ASM cells [33], HT-29 [34]
and lung fibroblasts [35], demonstrating p50 and p65 NF-kB
involvement in gene expression regulation under inflammatory
conditions, such as COX-2 induction. There were no statistical
differences in translocation dynamics and nuclear concentrations
of p65 and p50 proteins between NM and NP-AIA fibroblasts,
suggesting that the nuclear translocation of NF-kB transcription
factors is not altered in NP-AIA fibroblasts. In contrast, Picado
et al. [36] reported a reduced NF-kB activity in NP-AIA samples
when measuring p65 and p50 subunits. These discrepancies could
be explained by the samples used (whole NP tissue explants), the
experimental design followed (unstimulated samples) and the
heterogeneity of NP-AIA tissues (some of the patients were
receiving nasal corticosteroids before surgery).
In our study, the results obtained for the NF-kB subunit p52 did
not show any variation after IL-1b induction, suggesting that p52
is not activated under the experimental conditions used in the
study. Similarly, C/EBP isoform assessment revealed no changes
after IL-1b incubation, suggesting that C/EBPs are not activated
through the IL-1b pathway in either NM or NP-AIA fibroblasts.
C/EBP involvement in COX-2 regulation has been demonstrated
in several cell models, such as macrophages [37] and human
foreskin fibroblasts [38]. However, the stimuli used in these studies
were endotoxin and PMA, respectively, and this difference may
account for the C/EBP activation found in these experimental
models.
We could not find any differences in the nuclear translocation of
p65, p50 and C/EBP isoforms in NP-AIA fibroblasts compared to
NM fibroblasts after IL-1b induction. This observation concurs
with the findings of Coward et al. [35], who demonstrated that the
expression of p65 and C/EBPb was unaltered in fibroblasts from
idiopathic pulmonary fibrosis patients compared to control
fibroblasts, a disease that is also characterized by down-regulated
COX-2 expression in fibroblasts.
In summary, our study demonstrates that only p38 MAPK plays
a role in COX-2 induction by IL-1b. Moreover, there were similar
nuclear translocation dynamics in the NF-kB subunits, and no
differences in C/EBP regulation were found in fibroblasts from
either NP-AIA or NM. In conclusion, in the present study we did
not find any alterations responsible for the COX-2 down-
regulation described in NP-AIA fibroblasts.
Finally, future studies should assess other mechanisms, such as
transcription factors binding ability to gene promoter, the activity
of histone acetyltransferases and deacetylases and mRNA stability,
which could be crucial to understanding the observed down-
regulation of COX-2 in aspirin-induced asthma.
Figure 4. Time-course of p65 and p50 nuclear translocation induced by IL-1b in nasal fibroblast cultures. Fibroblasts from nasal mucosa
(NM, N = 3, black spots) and nasal polyps from AIA patients (NP-AIA, N = 3, white spots) were incubated with IL-1b (10 ng/ml) for 5 to 60 min. p65 (A)
and p50 (B) nuclear translocation were measured by TransAMH and Western blot. Graphs show the fold change increase from individual experimental
results and lines indicate the medians values. Insets show representative Western blot images of p65 (A) and p50 (B) subunits from both NM and NP-
AIA fibroblasts and the loading control b-actin. No significant differences (NS by Mann-Whitney U-test) were found at any time between NM and NP-
AIA fibroblasts.
doi:10.1371/journal.pone.0051281.g004
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Supporting Information
Figure S1 Time-course of c/EBPa and c/EBPb nuclear
translocation induced by IL-1b in nasal fibroblast cultures.
Fibroblasts from nasal mucosa (NM, N = 3, black spots) and nasal
polyps from AIA patients (NP-AIA, N = 3, white spots) were
incubated with IL-1b (10 ng/ml) for 5 to 60 min. c/EBPa (A) and
c/EBPb (B) nuclear translocation were measured by TransAMH.
Graphs show the fold change increase from individual experi-
mental measures and the medians. No significant differences (NS
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